Grant: Proof of Principle Program - Phase I
McGill University
$159,946.00
Targeting Alpha-Synuclein Propagation in the Treatment of Parkinson's Disease and Other Synucleinopathies
FY 2013-14
Summary
There are currently no therapies that alter disease progression for Parkinson's disease (PD), Multiple System Atrophy (MSA) or Dementia with Lewy Bodies (DLB). These diseases all feature Synuclein aggregation inside brain cells and hence they are called synucleinopathies. The gradual cell-to-cell spread of pathogenic Synuclein across the nervous system is a proposed mechanism for disease progression in synucleinopathies. This mechanism has recently been validated in animal models of the diseases; findings which reinforce observations from patients. By combining the PD expertise of Dr. Edward Fon, a clinician-scientist from the Montreal Neurological Institute at McGill University, and the drug development expertise of the Centre for Drug Research and Development (CDRD) in Vancouver, we recently optimized a high-throughput assay for the cellular uptake of pathogenic Synuclein and exploited this to uncover several small molecules which inhibit the process. Using a combination of secondary assays we selected two compounds in particular that stop Synuclein uptake into cells. These compounds are the subject of a submitted provisional patent application. We propose to characterize and optimize the drug-like properties of the compounds. The optimized novel compounds will be tested in an animal model of PD. As no satisfactory therapies exist for synucleinopathies, the opportunities in this market and the potential benefits to patients are both substantial.
Department
Program
Proof of Principle Program - Phase I
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
308073
Name
Fon Edward A
Region
Québec
Country
Canada
Orgtype
Research Institution; Institution Paid
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Proof of Principle
Projecttitle
Targeting Alpha-Synuclein Propagation in the Treatment of Parkinson's Disease and Other Synucleinopathies
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$159,946
Cihrequipment2
$0
Programname2
Proof of Principle Program - Phase I
Keyworddelim
Parkinson'S Disease; Prion; Synuclein
Abstract
There are currently no therapies that alter disease progression for Parkinson's disease (PD), Multiple System Atrophy (MSA) or Dementia with Lewy Bodies (DLB). These diseases all feature Synuclein aggregation inside brain cells and hence they are called synucleinopathies. The gradual cell-to-cell spread of pathogenic Synuclein across the nervous system is a proposed mechanism for disease progression in synucleinopathies. This mechanism has recently been validated in animal models of the diseases; findings which reinforce observations from patients. By combining the PD expertise of Dr. Edward Fon, a clinician-scientist from the Montreal Neurological Institute at McGill University, and the drug development expertise of the Centre for Drug Research and Development (CDRD) in Vancouver, we recently optimized a high-throughput assay for the cellular uptake of pathogenic Synuclein and exploited this to uncover several small molecules which inhibit the process. Using a combination of secondary assays we selected two compounds in particular that stop Synuclein uptake into cells. These compounds are the subject of a submitted provisional patent application. We propose to characterize and optimize the drug-like properties of the compounds. The optimized novel compounds will be tested in an animal model of PD. As no satisfactory therapies exist for synucleinopathies, the opportunities in this market and the potential benefits to patients are both substantial.
Competitiondate
201402
Approvedterm2
1 yr 0 mth
Pinamesdelim
Fon, Edward A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $159,946~ $0~